To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 156 participants.
Also called NCT04659070
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 156 participants
- Sponsor
- Registry
-
NCT04659070
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT04659070. Randomized; triple masking; primary purpose treatment. Start 2020-07-15 (actual); primary completion 2022-05-19 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia
- Condition
- Primary Hypercholesterolemia
- Condition
- Hypertension
- Intervention (Drug)
- Experimental : Ezetimibe / Rosuvastatin + Telmisartan
- Intervention (Drug)
- Active comparator1 : Ezetimibe / Rosuvastatin
- Intervention (Drug)
- Active comparator2 : Telmisartan
- Lead sponsor
- Hanlim Pharm. Co., Ltd.
Record details
- Record id
cardio:ct-nct04659070- Content hash
cd1b09f8158353b3f74ce294ca1cab0c37017c0c0d1cc893b0c42c0d17fa8c16